Digestive Diseases and Sciences

, Volume 41, Issue 7, pp 1319–1326 | Cite as

Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia

  • Ika I. Peleg
  • Michael F. Lubin
  • George A. Cotsonis
  • W. Scott Clark
  • C. Mel Wilcox
Gastrointestinal Oncology


Our objective was to study the relationship between dispensed aspirin, nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs), steroidal antiinflammatory drugs (SAIDs), acetaminophen, calcium, psyllium, and multivitamin preparations and the risk for subsequent colorectal adenoma and adenocarcinoma. The design was a case-control study. The patient population was from a large municipal teaching hospital in Atlanta, Georgia. In logistic regression models, the risk of colorectal adenoma or adenocarcinoma decreased in the first two years of continuous NSAID use in a linear, time-dependent manner. The risk of colorectal neoplasia after two years of continuous NSAID use was reduced significantly (P<0.01) as compared to nonusers. Risk reduction appeared greater for adenocarcinoma than adenoma. The use of SAIDs, calcium, multivitamins, and psyllium, as prescribed to our patient population during the mean six-year study period, conferred no measurable risk reduction. These results suggest that in prospective chemoprevention trials, a significant risk reduction can be expected after only two years of aspirin use, in doses similar to those recommended for the prevention of cardiovascular disease, or nonaspirin. NSAIDs, in doses commonly prescribed for the management of musculoskeletal pain. The results also imply that any short-term reduction in the incidence of colorectal adenoma detected in a phase II trial would underestimate the chemopreventive effect of NSAIDs on the risk of adenocarcinoma.

Key words

colon cancer nonsteroidal antiinflammatory drugs adenoma chemoprevention 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA 44:27–43, 1994Google Scholar
  2. 2.
    Potter JD, Slattery ML, Bostick RM, Gapstur SM: Colon cancer: A review of the epidemiology. Epidemiol Rev 15:499–545, 1993Google Scholar
  3. 3.
    Zimmerman J: Does dietary calcium supplementation reduce the risk of colon cancer? Nutr Rev 51:109–112, 1993Google Scholar
  4. 4.
    Dwyer J: Dietary fiber and colorectal cancer risk. Nutr Rev 51:147–155, 1993Google Scholar
  5. 5.
    Ausman LM: Fiber and colon cancer: Does the current evidence justify a preventive policy? Nutr Rev 51:57–63, 1993Google Scholar
  6. 6.
    Baron JA, Greenburg ER: Could aspirin really prevent colon cancer. N Engl J Med 325:1644–1646, 1991Google Scholar
  7. 7.
    Farmer KC, Goulston K, Mcrae F: Aspirin and non-steroidal anti-inflammatory drug in the chemoprevention of colorectal cancer. Med J Aust 159:649–650, 1993Google Scholar
  8. 8.
    Greenburg ER, Baron JA: Prospects for preventing colorectal cancer death. J Natl Cancer Inst 85:1182–1183, 1993Google Scholar
  9. 9.
    Paganini-Hill A: Aspirin and colorectal cancer. Br Med J 307:278–279, 1993Google Scholar
  10. 10.
    Waterhouse DM, Brenner D: Aspirin, NSAIDS and risk reduction of colorectal cancer Arch Interm Med 154:366–367, 1994Google Scholar
  11. 11.
    Baron JA, Adami AO: A broad anticancer effect of aspirin? Epidemiology 5:133–134, 1994Google Scholar
  12. 12.
    Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52:5575–5589, 1992Google Scholar
  13. 13.
    Earnest DJ, Hixson LJ, Alberts DS: Pirioxicam and other cyclooxygenase inhibitors: A potential for cancer chemoprevention. J Cell Biochem Suppl 161:156–166, 1992Google Scholar
  14. 14.
    Turner D, Berkel HJ: Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. Can Med Assoc J 149:595–602, 1993Google Scholar
  15. 15.
    Waddell WR: The effect of sulindac on colon polyps: Circumvention of a transformed phenotype—a hypothesis. J Surg Oncol 55:52–55, 1994Google Scholar
  16. 16.
    Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations, and medications: Case-control results from the Melbourne colorectal cancer study. Cancer Res 48:4399–4404, 1988Google Scholar
  17. 17.
    Rosenburg L, Palmer RJ, Zauber AG, Warshauer ME, Stolley PD: A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355–358, 1991Google Scholar
  18. 18.
    Peleg I, Maibach HT, Brown SH, Wilcox, CM: Aspirin and nonsteroidal antiinflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 154:394–399, 1994Google Scholar
  19. 19.
    Suh O, Mettlin C, Petrelli NJ: Aspirin use, cancer and polyps of the large bowel. Cancer 72:1171–1177, 1993Google Scholar
  20. 20.
    Logan RFA, Little J, Hatwin PG, Hardcastle JD: Effect of aspirin and nonsteroidal anti-inflammatory drugs on the risk of colorectal adenomas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br Med J 307:285–288, 1993Google Scholar
  21. 21.
    Greenburg ER, Baron JA, Freeman DH, Mandel JS, Haile R: Reduced risk of large bowel adenomas among aspirin users. J Natl Cancer Inst 85:912–916, 1993Google Scholar
  22. 22.
    Thun MJ, Nambroodiri MN, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596, 1991Google Scholar
  23. 23.
    Thun MJ, Calle EE, Nambroodiri MM, Heath CW Jr., et al: Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst 84:1491–1500, 1992Google Scholar
  24. 24.
    Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146, 1994Google Scholar
  25. 25.
    Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: A cohort study in the elderly. Br Med J 299:1247–1250, 1989Google Scholar
  26. 26.
    Paganini-Hill A, Hsu G, Ross RK, Henderson BE: Aspirin use and incidence of large-bowel in a California retirement community J Natl Cancer Inst 83:1182–1183, 1991 (letter)Google Scholar
  27. 27.
    Paganini-Hill A, Hsu G, Ross RK, Henderson BE: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 326:1290, 1992 (letter)Google Scholar
  28. 28.
    Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH: Low-dose aspirin use and the incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220–1224, 1993Google Scholar
  29. 29.
    Muscat JE, Stellman SD, Wynder EL: Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 74:1846–1857, 1994Google Scholar
  30. 30.
    Tempero MA: Progress in chemoprevention of gastrointestinal cancer. Curr Opin Oncol 3:719–726, 1991Google Scholar
  31. 31.
    Walker HK, Camp H, Brown S: The THERESA on-line medical record. Presentation to the Society of General Internal Medicine 14th Annual Meeting May 1, 1990Google Scholar
  32. 32.
    BMDP Statistical Software Inc. v. 1993, Los Angeles, California 90025Google Scholar
  33. 33.
    Bedenne L, Faivre J, Boutron MC, et al: Adenoma-carcinoma sequence or “de novo” carcinogenesis? A study of adenomatous remenants in a population-based series of large bowel cancer. Cancer 69:883–888, 1992Google Scholar
  34. 34.
    Horm JW, Asire AJ, Young AJ, Jr. Pollack ES: SEER program: Cancer incidence and mortality in the United States 1973–1981. NIH Publication 85-1873, Bethesda, Maryland 20205, National Cancer InstituteGoogle Scholar
  35. 35.
    Smigel K: Aspirin's next conquest: Does it prevent colorectal cancer? J Natl Cancer Inst 86:166–168, 1994Google Scholar
  36. 36.
    Cairns J, Cohen L, Colton T, et al: Issues in the early termination of the aspirin component of the Physicians' Health Study. Ann Epidemiol 1:395–405, 1991Google Scholar
  37. 37.
    Physician's Desk Reference. Medical Economics Data 1992, p 1447Google Scholar
  38. 38.
    DuBois RN: Nonsteroidal anti-inflammatory drug use and sporadic colorectal adenoma. Gastroenterology 108:A478, 1995Google Scholar
  39. 39.
    Hanif R, Pittas A, Feng Y, Koutsos MI, Shiff SJ, Staiano-Coico L, Rigas B: NSAIDs inhibit the cell growth of colon cancer cell lines by a prostaglandin independent pathway. Gastroenterology 108:A478, 1995Google Scholar
  40. 40.
    Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 157:175–179, 1989Google Scholar
  41. 41.
    Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115:952–955, 1991Google Scholar
  42. 42.
    Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316, 1993Google Scholar
  43. 43.
    Labayle D, Fischer D, Viehl P, Drouhin F, Pariente F, Bories C, Duhamel O, Trousset M, Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639, 1991Google Scholar
  44. 44.
    Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM: Adenomatous lesions of the large bowel. Cancer 43:1847–1857, 1979Google Scholar
  45. 45.
    Eddy DM: Screening for colorectal cancer. Ann Intern Med 113:373–384, 1990Google Scholar

Copyright information

© Plenum Publishing Corporation 1996

Authors and Affiliations

  • Ika I. Peleg
    • 1
    • 2
    • 3
    • 4
  • Michael F. Lubin
    • 1
    • 2
    • 3
    • 4
  • George A. Cotsonis
    • 1
    • 2
    • 3
    • 4
  • W. Scott Clark
    • 1
    • 2
    • 3
    • 4
  • C. Mel Wilcox
    • 1
    • 2
    • 3
    • 4
  1. 1.From the Clifton Center for Digestive Diseases, Department of MedicineUniversity of Iowa Hospitals and ClinicsIowa City
  2. 2.Department of MedicineEmory University School of MedicineAtlantaGeorgia
  3. 3.the Department of BiostatisticsEmory University School of Public HealthAtlantaGeorgia
  4. 4.Medical ServiceGrady Memorial HospitalAtlantaGeorgia

Personalised recommendations